Research ArticlePharmaceutics, Drug Delivery and Pharmaceutical TechnologyA Dual-Ligand Liposomal System Composed of a Cell-Penetrating Peptide and a Mitochondrial RNA Aptamer Synergistically Facilitates Cellular Uptake and Mitochondrial Targeting
Introduction
If it was possible to develop an active targeting system that could target a specific organelle, this would open a new field of research directed toward therapy for various diseases. Mitochondria are promising targets for delivering therapeutic molecules.1 Mitochondrial dysfunctions are implicated in a variety of human diseases, including neurodegenerative disorders, ischemia reperfusion injury, cancer, and inherited mitochondrial diseases.2, 3, 4, 5 Accordingly, it would be expected that delivering therapeutic molecules to mitochondria in diseased cells be a strategy for the treatment of mitochondrial dysfunctions, resulting in the suppression of mitochondria-related diseases.
The mitochondrial targeting signal peptide, which is necessary for targeting nuclear-encoded protein to mitochondria, is useful as a specific ligand for mitochondria.6, 7 Previous reports showed that the conjugation or direct modification of mitochondrial targeting signal peptide permitted a macromolecule, such as a protein, DNA, and a liposomal nanocarrier to be delivered to mitochondria.8, 9, 10, 11, 12 On the other hand, some researchers have reported the use of a mitochondrial RNA aptamer for mitochondrial delivery. The mitochondrial import of mitochondrial ribozyme, RNase P (RP), and mitochondrial RNase P (MRP) were reported to be mediated by polynucleotide phosphorylase.13 Wang et al.13, 14 showed that allotropically encoded mitochondrial mRNAs and transfer RNA (tRNA) were imported by RP and MRP aptamers into mitochondria. Adhya et al.15 reported that the combination of a mitochondrial tRNA import signal (D-arm) and a RNA import complex, which were found in Leishmania tropica, induced the transport of tRNA and antisense RNA into mitochondria in living cells. However, the direct modification of a mitochondrial RNA aptamer on a nanocarrier has not been a subject of extensive investigation.
The present study focused on enhancing mitochondrial targeting by modification of a liposomal-based nanocarrier with a mitochondrial RNA aptamer. The mitochondrial RNA aptamers used in this study included RP and MRP, in which mitochondrial delivery occurs through polynucleotide phosphorylase,13 and the D-arm with a high affinity with the tubulin antisense–binding protein located on the mitochondrial outer membrane16 (Table 1). These RNA aptamers themselves have mitochondrial targeting activity, but modifying the carrier with a single aptamer would not be sufficient to allow the particle to be internalized by a cell. We recently reported on the development of a mitochondrial delivery system, a MITO-Porter in which the surface is modified with octaarginine (R8). The R8 functions as both a cellular uptake device through macropinocytosis and as a mitochondrial targeting peptide through electrostatic interactions with negatively charged mitochondria.17, 18, 19 We also developed a dual-ligand system in which the nanocarrier is modified with a specific ligand and R8.20, 21 These systems have a synergistic effect on both selectivity and cellular uptake.
Thus, we expected that a dual-ligand liposomal system modified with both R8 and a mitochondrial RNA aptamer would show an enhanced mitochondrial delivery. In this study, we prepared a dual-ligand–modified MITO-Porter composed of R8 with different amounts of mitochondrial RNA aptamers including RP, MRP, and the D-arm. We then evaluated the cellular uptake efficiency of the carriers using flow cytometry. The extent of intracellular trafficking was observed by confocal laser scanning microscopy (CLSM), and the mitochondrial targeting rate and mitochondrial occupancy rate were estimated based on the obtained CLSM images.
Section snippets
Chemicals and Materials
1,2-Dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), sphingomyelin, and DOPE-N-(7-nitro-2-1,3-benzoxadiazole-4-yl) (NBD-DOPE) were purchased from Avanti Polar lipids (Alabaster, AL). Stearylated R822 was obtained from KURABO Industries (Osaka, Japan). Cholesterol covalently linked to the 3′ end of 2′-O-methyl RNAs (Chol-RNA aptamer) containing the RP sequence (Chol-RP), MRP sequence (Chol-MRP), and the D-arm sequence (Chol-D-arm) were obtained from Hokkaido System Science Co., Ltd. (Sapporo,
Construction of Dual-Ligand–Modified MITO-Porter
Chol-RNA aptamers, including RP, MRP, and the D-arm, were used to prepare the dual-ligand–modified MITO-Porter (RP/R8-modified MITO-Porter, MRP/R8-modified MITO-Porter, and D-arm/R8-modified MITO-Porter). Information regarding the RNA aptamers used in this study is listed in Table 1. The physicochemical properties of the prepared carriers are summarized in Table 2. Their diameters were approximately 100-150 nm. Modification of a negatively charged RNA aptamer on the positively charged
Discussion
The present study focused on strategies for enhancing mitochondrial targeting by modification of a liposomal-based nanocarrier with a mitochondrial RNA aptamer. To evaluate the targeting of the nanocarrier to mitochondria in living cells, we developed a dual-ligand system, in which the nanocarrier is modified with a mitochondrial RNA aptamer and R8. We expected that R8, which is reported to function as a cellular uptake device for a liposomal carrier,17, 18, 19 would assist the cellular
Conclusions
The results presented here constitute the first report of the use of a mitochondrial RNA aptamer–modified nanocarrier system to regulate intracellular trafficking, although lipophilic and cationic peptide-based mitochondrial targeting have been reported in previous studies.12, 19, 33, 34, 35 In this study, we determined the optimal dual-ligand system for a nanocarrier for achieving efficient cellular uptake and mitochondrial targeting (RP/R8-modified MITO-Porter). However, more improvements in
Acknowledgments
This work was supported, in part, by a Grant-in-Aid for Scientific Research (B) (grant 26282131 to Y.Y.) from the Ministry of Education, Culture, Sports, Science, and Technology, the Japanese Government (MEXT), the Mochida Memorial Foundation for Medical and Pharmaceutical Research, and the Uehara Memorial Foundation. We also thank Dr. Milton Feather for his helpful advice in writing the manuscript.
References (36)
Mitochondria: dynamic organelles in disease, aging, and development
Cell
(2006)Mitochondrial disease
Lancet
(2006)- et al.
Newly developed strategies for multifunctional mitochondria-targeted agents in cancer therapy
Drug Discov Today
(2011) - et al.
Delivery of drugs and macromolecules to mitochondria
Adv Drug Deliv Rev
(2007) - et al.
Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases
Adv Drug Deliv Rev
(2008) - et al.
Recombinant mitochondrial transcription factor A protein inhibits nuclear factor of activated T cells signaling and attenuates pathological hypertrophy of cardiac myocytes
Mitochondrion
(2012) - et al.
Targeted delivery of DNA to the mitochondrial compartment via import sequence-conjugated peptide nucleic acid
Mol Ther
(2003) - et al.
Enhancement in selective mitochondrial association by direct modification of a mitochondrial targeting signal peptide on a liposomal based nanocarrier
Mitochondrion
(2013) - et al.
Intracellular observation of nanocarriers modified with a mitochondrial targeting signal peptide
J Biosci Bioeng
(2013) - et al.
PNPASE regulates RNA import into mitochondria
Cell
(2010)
Mitochondrial gene therapy: the tortuous path from bench to bedside
Mitochondrion
Role of an RNA-binding protein in import of tRNA into Leishmania mitochondria
J Biol Chem
MITO-Porter: a liposome-based carrier system for delivery of macromolecules into mitochondria via membrane fusion
Biochim Biophys Acta
Dual function MITO-Porter, a nano carrier integrating both efficient cytoplasmic delivery and mitochondrial macromolecule delivery
Mol Ther
Multifunctional envelope-type nano device for controlled intracellular trafficking and selective targeting in vivo
J Control Release
Size-controlled, dual-ligand modified liposomes that target the tumor vasculature show promise for use in drug-resistant cancer therapy
J Control Release
Dual-ligand modification of PEGylated liposomes shows better cell selectivity and efficient gene delivery
J Control Release
The emergence of clathrin-independent pinocytic pathways
Curr Opin Cell Biol
Cited by (32)
In-situ bio-assembled specific Au NCs-Aptamer-Pyro conjugates nanoprobe for tumor imaging and mitochondria-targeted photodynamic therapy
2022, Biosensors and BioelectronicsMitochondrion-targeted RNA therapies as a potential treatment strategy for mitochondrial diseases
2022, Molecular Therapy Nucleic AcidsCardiac Mitochondrial Transplantation: The Force Awakens
2021, Journal of the American College of CardiologyEvolution of drug delivery system from viewpoint of controlled intracellular trafficking and selective tissue targeting toward future nanomedicine
2020, Journal of Controlled ReleaseCitation Excerpt :We focused on the fact that mitochondria are continuously repeating fusion and fission in living cells and this permits bio macromolecules (nucleic acids, mtDNA, proteins and etc) to be shared between mitochondria, and we proposed the concept of a MITO-Porter, a liposome to achieve mitochondrial delivery of various types of cargoes via a membrane fusion. We successfully identified highly fusible mitochondrial fusogenic lipid compositions for this purpose [9,70–72]. A MITO-Porter, a particle in which the surface is modified with the membrane-permeable peptide (R8) is efficiently taken up by cells.
Power of mitochondrial drug delivery systems to produce innovative nanomedicines
2020, Advanced Drug Delivery Reviews
The authors Yuma Yamada and Ryo Furukawa contributed equally.
This article contains supplementary material available from the authors by request or via the Internet at http://dx.doi.org/10.1016/j.xphs.2016.03.002.